title: Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.
abstract: To determine the maximum tolerated dose (MTD) and assess the toxicity profile and pharmacokinetics of weekly gemcitabine infusions in pediatric patients with refractory hematologic malignancies. Fourteen patients under 21 years old were given infusions of gemcitabine for escalating durations at 10 mg/m2/min weekly for three consecutive weeks. Two males and two females were studied at each dose level. Pharmacokinetics of the drug's metabolism were measured by high pressure-liquid chromatography (HPLC) for 24 h after the first dose. Intracellular difluorodeoxycytidine triphosphate formation in leukemic blasts was measured in selected patients. The MTD of gemcitabine in these patients was 3600 mg/m2/week for three consecutive weeks (10 mg/m2/min for 360 min). Hepatotoxicity was the dose limiting toxicity. Thirty to fifty percent of patients exhibited fever, rash, or myalgia. Rare instances of hypotension and pulmonary toxicity were observed. Two of six patients [one acute lymphoblastic leukemia (ALL) and one acute myelogenous leukemia (AML)] treated at the MTD had at least M2 marrows, although peripheral blood counts did not recover sufficiently for the patients to be considered in complete response. Pharmacokinetics of gemcitabine fit a two-compartment open model with terminal half-life and plasma clearance value of 62 min and 2.2 l/min/m2, respectively. No gender differences were observed. In conclusion, the MTD of gemcitabine was 10 mg/m2/min for 360 min every week for 3 weeks. This is the recommended phase II dose schedule for children with leukemia. The activity of the drug at this schedule in heavily pretreated, refractory patients warrants a phase II trial in hematologic malignancies.
authors.affiliation: steinhep@mskcc.org
authors.forename: P G
authors.initials: PG
authors.lastname: Steinherz
authors.forename: N L
authors.initials: NL
authors.lastname: Seibel
authors.forename: M M
authors.initials: MM
authors.lastname: Ames
authors.forename: V I
authors.initials: VI
authors.lastname: Avramis
authors.forename: M D
authors.initials: MD
authors.lastname: Krailo
authors.forename: W
authors.initials: W
authors.lastname: Liu-Mares
authors.forename: J M
authors.initials: JM
authors.lastname: Reid
authors.forename: S L
authors.initials: SL
authors.lastname: Safgren
authors.forename: G H
authors.initials: GH
authors.lastname: Reaman
mesh_terms: D000293:Adolescent; D001711:Biotransformation; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008657:Metabolic Clearance Rate; D016879:Salvage Therapy / Q000379:methods*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine